Compare BRUN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRUN | DRTS |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2026 | 2021 |
| Metric | BRUN | DRTS |
|---|---|---|
| Price | $6.12 | $13.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $42.75 | $17.80 |
| AVG Volume (30 Days) | ★ 4.0M | 472.4K |
| Earning Date | 11-12-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $550.82 | N/A |
| Revenue Next Year | $214.84 | $1,235.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.62 | $3.43 |
| 52 Week High | $40.46 | $15.79 |
| Indicator | BRUN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 32.25 | 51.90 |
| Support Level | N/A | $13.73 |
| Resistance Level | $26.68 | $13.95 |
| Average True Range (ATR) | 0.82 | 0.67 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 17.89 | 76.47 |
Boost Run Inc is an NVIDIA Cloud Provider. Its platform provides GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. Enterprises rely on Boost Run to power their main demanding AI workloads with the performance, security, and reliability their operations require. The group maintains SOC 2 Type II, HIPAA, ISO 27001, and ISO 27701 certifications at the operator level, and partners with data center facilities that uphold equivalent security and compliance standards.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.